A Prospective Multi-centre, Randomised, Controlled Study to Evaluate the Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Fusion (L1 - S1)
Latest Information Update: 24 Jun 2021
At a glance
- Drugs NVD-001 (Primary)
- Indications Spondylolisthesis
- Focus Adverse reactions
- Acronyms Spine1
- Sponsors Novadip Biosciences
Most Recent Events
- 24 Jun 2021 New trial record